← Leaderboards

Stephen A Spector

University Of California, San Diego

Google Scholar ↗PubMed ↗ORCID ↗

$131,199,154

Attributed

$133,617,212

Total exposure

41

Grants

30

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $15.4M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$133,617,212 · 41

By mechanism

U01$89,242,901 · 5

UM1$32,602,811 · 1

R01$9,966,196 · 4

R56$717,283 · 1

M01$486,943 · 26

R21$422,944 · 1

Top collaborators

Most similar at University Of California, San Diego

Same institution · by research overlap

David J Moore$20,232,553

Others in their field

Top investigators on “Hiv Infections”

Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
Judith S. Currier · University Of California Los Angeles$466,447,923
Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678

Research focus

Hiv InfectionsResearch PersonnelClinical TrialsClinical ResearchInfectionFundingAntiretroviral TherapySiteChildPreventAnti-Retroviral AgentsBaseAids TherapyAdolescentHuman SubjectUniversitiesTransmission ProcessPediatric AidsPersonsPerinatalProtocols DocumentationCaliforniaAids Education /PreventionArea

Grant awards (99)

CURE CTU$2,404,040

UM1 · FY2025 · AI · contact PI

CURE CTU$1,845,017

UM1 · FY2025 · AI · contact PI

HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)$1,985,586

UM1 · FY2024 · AI · contact PI

HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)$2,149,542

UM1 · FY2023 · AI · contact PI

Single Cell Transcriptomics of the Cocaine Use Disorder in the Context of HIV$1,527,174

U01 · FY2023 · DA

HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)$2,030,179

UM1 · FY2022 · AI · contact PI

Single Cell Transcriptomics of the Cocaine Use Disorder in the Context of HIV$1,561,951

U01 · FY2022 · DA

HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)$2,047,069

UM1 · FY2021 · AI · contact PI

Nanopeptide Targeting of HIV-CNS Reservoirs without Reactivation$649,766

R01 · FY2021 · NS · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)$3,241,549

UM1 · FY2020 · AI · contact PI

Nanopeptide Targeting of HIV-CNS Reservoirs without Reactivation$649,766

R01 · FY2020 · NS · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU) Administrative Supplement$300,054

UM1 · FY2020 · AI · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)$3,372,423

UM1 · FY2019 · AI · contact PI

Nanopeptide Targeting of HIV-CNS Reservoirs without Reactivation$598,306

R01 · FY2019 · NS · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)$2,149,178

UM1 · FY2018 · AI · contact PI

Nanopeptide Targeting of HIV-CNS Reservoirs without Reactivation$495,027

R01 · FY2018 · NS · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)$2,074,220

UM1 · FY2017 · AI · contact PI

Nanopeptide Targeting of HIV-CNS Reservoirs without Reactivation$494,678

R01 · FY2017 · NS · contact PI

Modulating Autophagy to Eradicate HIV-1 from CNS Reservoirs$383,700

R01 · FY2017 · NS · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)$2,074,220

UM1 · FY2016 · AI · contact PI

Modulating Autophagy to Eradicate HIV-1 from CNS Reservoirs$397,450

R01 · FY2016 · NS · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)$2,046,978

UM1 · FY2015 · AI · contact PI

Host Genetic Factors Associated with CNS Disease of HIV-Infected Children$685,433

R01 · FY2015 · NS · contact PI

Modulating Autophagy to Eradicate HIV-1 from CNS Reservoirs$387,500

R01 · FY2015 · NS · contact PI

HIV CENTERS FOR UNDEREPRESENTED POPULATIONS IN RESEARCH CTU (HIV CURE CTU)$2,642,740

UM1 · FY2014 · AI · contact PI

Role of CMV in Heart Disease of HIV-Infected Women and Perinatally Infected Youth$717,283

R56 · FY2014 · HL · contact PI

Host Genetic Factors Associated with CNS Disease of HIV-Infected Children$698,980

R01 · FY2014 · NS · contact PI

Modulating Autophagy to Eradicate HIV-1 from CNS Reservoirs$383,625

R01 · FY2014 · NS · contact PI

University of California, San Diego Clinical Trial Unit$1,227,553

UM1 · FY2013 · AI · contact PI

Host Genetic Factors Associated with CNS Disease of HIV-Infected Children$702,067

R01 · FY2013 · NS · contact PI

Modulating Autophagy to Eradicate HIV-1 from CNS Reservoirs$387,500

R01 · FY2013 · NS · contact PI

University of California, San Diego Clinical Trial Unit$1,012,463

UM1 · FY2012 · AI · contact PI

Host Genetic Factors Associated with CNS Disease of HIV-Infected Children$742,181

R01 · FY2012 · NS · contact PI

University of California, San Diego Clinical Trial Unit$1,051,329

U01 · FY2011 · AI · contact PI

Host Genetic Factors Associated with CNS Disease of HIV-Infected Children$790,634

R01 · FY2011 · NS · contact PI

University of California, San Diego Clinical Trial Unit$1,062,445

U01 · FY2010 · AI · contact PI

Vitamin D Inhibition of HIV and M. Tuberculosis Coinfection in Macrophages$191,194

R21 · FY2010 · AI · contact PI

ADOLESCENT MASTER PROTOCOL (AMP) - IMPACT OF HIV AND ART ON GROWTH$10,534

M01 · FY2010 · RR · contact PI

HEALTHY SUBJECT CELL COLLECTION$8,284

M01 · FY2010 · RR · contact PI

CLINICAL TRIAL: IMPAACT 1071$1,215

M01 · FY2010 · RR · contact PI

CLINICAL TRIAL: ANTIRETROVIRAL ACTIVITY OF RALTEGRAVIR IN HIV-1 INFECTED CHILDRE$405

M01 · FY2010 · RR · contact PI

University of California, San Diego Clinical Trial Unit$1,120,724

U01 · FY2009 · AI · contact PI

Vitamin D Inhibition of HIV and M. Tuberculosis Coinfection in Macrophages$231,750

R21 · FY2009 · AI · contact PI

CCTG 560A: VIRAL POPULATION KINETICS$33,027

M01 · FY2009 · RR · contact PI

HEALTHY SUBJECT CELL COLLECTION$25,478

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: PACTG 1020A NOVEL PROTEASE INHIBITOR BMS-232632 IN CHILDREN WITH$18,579

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: PACTG P1025 PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS$8,255

M01 · FY2009 · RR · contact PI

ADOLESCENT MASTER PROTOCOL (AMP) - IMPACT OF HIV AND ART ON GROWTH$6,197

M01 · FY2009 · RR · contact PI

University of California, San Diego Clinical Trial Unit$1,127,587

U01 · FY2008 · AI · contact PI

HEALTHY DONOR CELLS$32,972

M01 · FY2008 · RR · contact PI

ADOLESCENT MASTER PROTOCOL (AMP) - IMPACT OF HIV AND ART ON GROWTH$29,634

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: PACTG P1025 PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS D$19,759

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: PACTG 1020A NOVEL PROTEASE INHIBITOR BMS-232632 IN CHILDREN WITH$14,817

M01 · FY2008 · RR · contact PI

University of California, San Diego Clinical Trial Unit$1,038,179

U01 · FY2007 · AI · contact PI

Virology$178,134

P30 · FY2007 · AI · contact PI

HEALTHY DONOR CELLS$32,559

M01 · FY2007 · RR · contact PI

PACTG 1020A NOVEL PROTEASE INHIBITOR BMS-232632 IN CHILDREN WITH HIV$21,740

M01 · FY2007 · RR · contact PI

PACTG P1025 PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY$5,017

M01 · FY2007 · RR · contact PI

PACTG P1021 EMTRICITABINE AND EFAVIRENZ AND DIDANOSINE IN HIV$5,017

M01 · FY2007 · RR · contact PI

Pediatric AIDS Clinical Trials Group$785,626

U01 · FY2006 · AI · contact PI

PACTG P1025 PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY$20,850

M01 · FY2006 · RR · contact PI

HEALTHY DONOR CELLS$19,972

M01 · FY2006 · RR · contact PI

PACTG 1020A NOVEL PROTEASE INHIBITOR BMS-232632 IN CHILDREN WITH HIV$14,337

M01 · FY2006 · RR · contact PI

PACTG P1039 ZIDOVUDINE/LAMIVUDINE/ABACAVIR IN PERINATAL HIV$1,302

M01 · FY2006 · RR · contact PI

Pediatric ACTG Coordinating and Operations Center$13,579,521

U01 · FY2005 · AI

Pediatric AIDS Clinical Trials Group$1,051,844

U01 · FY2005 · AI

ADOLESCENT MEDICINE TRIALS UNIT (AMTU)$411,568

U01 · FY2005 · HD

FACTORS IN PEDIATRIC AIDS TRANSMISSION AND PATHOGENESIS$304,000

R01 · FY2005 · AI

NORMAL DONOR CELLS FOR HIV ASSAYS$75,873

M01 · FY2005 · RR

PACTG P1025 PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUGS DURING PREGNANCY$7,821

M01 · FY2005 · RR

PACTG 1020A NOVEL PROTEASE INHIBITOR BMS-232632 IN CHILDREN WITH HIV$7,040

M01 · FY2005 · RR

ACTG 382 DMP 266 IN COMBINATION WIT NELFINAVIR IN CHILDREN WITH HIV$3,128

M01 · FY2005 · RR

PACTG P1052 ABACAVIR PK DURING CHRONIC THERAPY IN HIV INFECTION$1,565

M01 · FY2005 · RR

PACTG P1022 PROTEASE INHIBITOR-INCLUDING/SPARING FOR HIV DURING PREGNANCY$781

M01 · FY2005 · RR

Pediatric ACTG Coordinating and Operations Center$13,829,521

U01 · FY2004 · AI

Pediatric AIDS Clinical Trials Group$973,663

U01 · FY2004 · AI

ADOLESCENT MEDICINE TRIALS UNIT (AMTU)$551,372

U01 · FY2004 · HD

FACTORS IN PEDIATRIC AIDS TRANSMISSION AND PATHOGENESIS$304,000

R01 · FY2004 · AI

NORMAL DONOR CELLS$55,145

M01 · FY2004 · RR

PHARMACOKINETICS OF ANTIRETROVIRALS DURING PREGNANCY$2,506

M01 · FY2004 · RR

PACTG P1021 Emtricitabine/Efavirenz/Didanosine in HIV$1,254

M01 · FY2004 · RR

ACTG382--DMP 266 in Combination w/Nelfinavir in Children$1,254

M01 · FY2004 · RR

PROTEASE INHIBITOR INCLUDING SPARING FOR HIV PREGNANCY$626

M01 · FY2004 · RR

Pediatric ACTG Coordinating and Operations Center$13,434,001

U01 · FY2003 · AI

Pediatric AIDS Clinical Trials Group$885,194

U01 · FY2003 · AI

ADOLESCENT MEDICINE TRIALS UNIT (AMTU)$697,660

U01 · FY2003 · HD

FACTORS IN PEDIATRIC AIDS TRANSMISSION AND PATHOGENESIS$304,000

R01 · FY2003 · AI

Pediatric ACTG Coordinating and Operations Center$13,432,535

U01 · FY2002 · AI

Pediatric AIDS Clinical Trials Group$859,411

U01 · FY2002 · AI

ADOLESCENT MEDICINE TRIALS UNIT (AMTU)$578,408

U01 · FY2002 · HD

FACTORS IN PEDIATRIC AIDS TRANSMISSION AND PATHOGENESIS$304,000

R01 · FY2002 · AI

CORE -- ADOLESCENT MEDICAL TRIALS$0

P60 · FY2002 · MD

CORE -- ADOLESCENT MEDICAL TRIALS$0

P60 · FY2002 · MD

PEDIATRIC AIDS CLINICAL TRIALS GROUP--COORDINATE/OPERATE$8,607,329

U01 · FY2001 · AI

PEDIATRIC AIDS CLINICAL TRIALS GROUP$922,683

U01 · FY2001 · AI

FACTORS IN PEDIATRIC AIDS TRANSMISSION AND PATHOGENESIS$303,583

R01 · FY2001 · AI

ADOLESCENT MEDICINE TRIAL NETWORK FOR HIV/AIDS$215,428

U01 · FY2001 · HD

PEDIATRIC AIDS CLINICAL TRIALS GROUP--COORDINATE/OPERATE$9,031,018

U01 · FY2000 · AI

PEDIATRIC AIDS CLINICAL TRIALS GROUP$906,730

U01 · FY2000 · AI